Axsome Therapeutics, based in New York City, develops therapies for central nervous system disorders, with commercial products Auvelity and Sunosi, and investigational drugs AXS-05 and AXS-07. The company employs 545 staff and went public in November 2015.
Mark L Jacobson sold 25,000 shares of AXSM on 9 June at $110.44 per share, worth a total of $2.8M. They now own 5,783 AXSM shares, or a 81% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.